General Information
Revision date
2023-02-01
Product name
AND OF THE
Product Synonyms
adalimumab-otto
Chemical name
anti-TNF alpha monoclonal antibody
CAS No.
1446410-95-2
Emergency telephone
Amgen Inc
Icons in SDS
Company Information
company name
Amgen Inc
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Emergency Overview Pharmaceutical product intended for clinical and commercial manufacturing purposes only. Product contains adalimumab-otto, an active pharmaceutical ingredient for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis. Dosage contents may pose a health hazard only if significant absorption occurs (e.g. inhalation after a major spill or leak). Avoid inhalation, skin contact, eye contact, and accidental ingestions. Does not meet GHS classification criteria and therefore is not classified 2.1 - Classification of the drug substance or mixture (drug product in final form, not applicable)
2.2 Label elements
Not classified
Other hazards
No information available
